Assembly Biosciences, Inc. (ASMB), Thursday announced that the company has received a total of $30.1 million from Gilead Sciences, Inc.
Of the total amount, $20.1 million is an equity investment to purchase additional Assembly Bio common stock, increasing Gilead's ownership in the company to 29.9 percent.
Whereas, the remaining amount is in accelerated funding, which will be used to advance clinical pipeline of antiviral therapeutic candidates for herpesviruses, hepatitis D virus, and hepatitis B virus.
The biotechnology company expects its cash runway to extend to mid-2026 with the help of this latest investment and funding.
Currently, Assembly Bio's stock is trading at $15.28, up 13.11 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.